The Technology Behind Ingestible Insulin

Your next video will start in

Recommended Videos

  • Info

  • Comments


Oct. 22 (Bloomberg) -- Oramed CEO Nadav Kidron discusses the technology behind ingestible insulin on Bloomberg Television's "Money Moves." (Source: Bloomberg)

Take it orally because it gets migrated and because of the size.

What we have is a technology that allows you to take insulin and to deliver them orally by overcoming the problem of the size and the creation.

Might we see some kind of tie up with a larger pharmaceutical company?

I think our preference is to make a partnership at the right point in time where it makes sense for both parties.

I can tell you that it is such a unique technology that is allows a student -- allows us to deliver not only insulin but others.

A lot of companies are looking into oral technology.

You must build take this beyond a loan.

You either have to raise more money or be bought by another company, right?

Currently, oramed has about $8 million.

As an and -- as an israeli company we are able to get a lot done on a much smaller budget.

That is definitely the route we are looking at.

All right.

Dallas from tel aviv.

Of course, we aren't -- that was from tel

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change